FDA grants orphan drug status to Arbor Biotechnologies’ PH1
The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) and rare paediatric disease designation ...
BioWorld7d
Arbor’s ABO-101 awarded US orphan drug designation for primary hyperoxaluria type 1
Arbor Biotechnologies Inc.’s ABO-101 has been awarded orphan drug and rare pediatric disease designations by the FDA for the treatment of primary hyperoxaluria type 1 (PH1).
Kaleido Scope1mon
UAB named OHF Care Center for excellence in rare kidney stone disease research and clinical care
Primary hyperoxaluria is a significant kidney stone disease caused by the overproduction of the molecule oxalate. It can be diagnosed as primary hyperoxaluria type one, two or three, with type one ...
Canada6mon
Drugs for rare diseases: Common list of drugs
Poteligeo (Mycosis fungoides or Sézary syndrome) Oxlumo (Primary hyperoxaluria type 1) Epkinly (Relapsed or refractory diffuse large B-cell lymphoma) Welireg (Von Hippel-Lindau disease) Yescarta ...